葵花葯業(002737.SZ):擬設立全資子公司吉安公司、哈醫藥
格隆匯7月25日丨葵花葯業(002737.SZ)公佈,公司擬使用自有資金合計2,000萬元人民幣投資設立兩家全資子公司:葵花葯業大健康科技吉安有限公司(籌)(簡稱“吉安公司”)、葵花葯業集團(哈爾濱)醫藥有限公司(籌)(簡稱“哈醫藥”)。
本次投資設立全資子公司系公司基於整體發展戰略,旨在通過優化投資控股體系,實現營銷體系各業務板塊分線操作、獨立運營,優化資源配置,充分調動組織效能,提升公司整體運營效率。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.